Analysts at Credit Suisse AG and JPMorgan Chase & Co. have said AstraZeneca may undertake a bigger takeover to replace revenue that will be lost to generic competition. With the failure or delay in the past month of experimental drugs for diabetes, ovarian cancer and severe depression, the risk is increasing, said Credit Suisse’s Luisa Hector.
“They are gradually running out of options,” she said by telephone yesterday. Hector, who rates the stock “underperform,” declined to speculate on which companies may be a target or how much AstraZeneca might spend on an acquisition.
via businessweek.com
No comments:
Post a Comment